Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age‐ and sex‐matched population-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age‐ and sex‐matched population

Published:2023-12-15 Issue: Volume: Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Molica Stefano¹^ORCID,Shanafelt Tait D.²,Allsup David¹³^ORCID,Giannarelli Diana⁴

Affiliation:

1. Department of Hematology Hull University Teaching Hospitals NHS Trust Hull UK

2. Division of Hematology, Department of Medicine Stanford University School of Medicine Stanford California USA

3. Centre for Biomedicine Hull York Medical School Hull UK

4. Biostatistics Unit Scientific Directorate Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27182

Reference19 articles.

1. How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients with CLL?

2. Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy

3. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

4. Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

5. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The new life of ibrutinib therapy in CLL: enhancing personalized approaches;Expert Review of Anticancer Therapy;2024-07-15

2. Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints;Expert Review of Hematology;2024-06-13

3. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents;Cancers;2024-05-24

4. Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population;Cancers;2024-03-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3